Icosavax, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ICVX research report →
About the company
Icosavax, Inc. operates as a biopharmaceutical firm dedicated to developing immunizations against infectious diseases. Leveraging its proprietary virus-like particle (VLP) platform technology, the company primarily focuses its efforts on severe respiratory illnesses.
- CEO
- Adam K. Simpson
- IPO
- 2021
- Employees
- 60
- HQ
- Seattle, WA, US
Price Chart
- Market Cap
- $769.04M
- P/E
- -6.87
- P/S
- 1321.37
- P/B
- 2.79
- EV/EBITDA
- -7.63
- Div Yield
- 0.00%
- Gross Margin
- -216.67%
- Op Margin
- -16332.99%
- Net Margin
- -15198.97%
- ROE
- -35.64%
- ROIC
- -40.37%
- Revenue
- $582.00K · -92.54%
- Net Income
- $-88,458,000 · -30.09%
- EPS
- $-2.23 · 41.01%
- Op Income
- $-95,058,000
- FCF YoY
- -84.06%
- 52W High
- $16.11
- 52W Low
- $4.75
- 50D MA
- $14.98
- 200D MA
- $10.02
- Beta
- 1.28
- Avg Volume
- 1.05M
Get TickerSpark's AI analysis on ICVX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 19, 24 | RA CAPITAL MANAGEMENT, L.P. | sell | 17,000 |
| Feb 19, 24 | RA CAPITAL MANAGEMENT, L.P. | other | 638,668 |
| Feb 19, 24 | RA CAPITAL MANAGEMENT, L.P. | sell | 22,278 |
| Feb 19, 24 | Simpson Adam K. | other | 129,032 |
| Feb 19, 24 | Simpson Adam K. | sell | 317,866 |
| Feb 19, 24 | Simpson Adam K. | sell | 237,146 |
| Feb 19, 24 | Simpson Adam K. | sell | 375,000 |
| Feb 19, 24 | Simpson Adam K. | sell | 191,449 |
| Feb 19, 24 | Simpson Adam K. | sell | 1,347,546 |
| Feb 19, 24 | Simpson Adam K. | sell | 350,000 |
Our ICVX coverage
Recent articles, reports, and earnings notes.
No research on ICVX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ICVX report →Similar companies
Peers in the same neighborhood.